Rezvilutamide Bests Bicalutamide in Metastatic Prostate Cancer

(MedPage Today) -- In combination with androgen deprivation therapy (ADT), the novel androgen-receptor inhibitor rezvilutamide significantly improved radiographic progression-free survival (PFS) and overall survival (OS) compared with bicalutamide...